Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxol + cisplatin chemotherapy versus Taxol + cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in metastatic esophageal squamous cell carcinoma
ChiCTR-TRC-13005027Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoints: Progression-free survival, Median survival time and 2 more. Planned start Mar 2015; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13005027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13005027.